Navigation Links
Intercept Pharmaceuticals to Collaborate With NIDDK on Study of Obeticholic Acid (INT-747) in Nonalcoholic Steatohepatitis (NASH)
Date:7/28/2010

NEW YORK, July 28 /PRNewswire/ -- Intercept Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing novel therapeutics for chronic fibrotic and metabolic diseases, today announced the signing of a cooperative research and development agreement (CRADA) with the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health to conduct a double blind, multi-center, study to evaluate the effects of obeticholic acid in patients with nonalcoholic steatohepatitis (NASH). Obeticholic acid is the generic name for INT-747, Intercept's first-in-class FXR agonist.

The planned study will enroll 280 patients at the eight U.S. centers constituting the NIDDK-sponsored NASH clinical research network (CRN), which will make it the largest study conducted in this disease.  The objectives of the 72 week study will be to assess whether obeticholic acid improves histological disease activity and other disease markers, along with the safety of the drug in this patient population. The study is expected to begin in the fourth quarter of 2010 and the NIDDK will provide a majority of the funding needed under the CRADA.

NASH is a more serious form of nonalcoholic fatty liver disease (NAFLD) and occurs in patients who drink little or no alcohol. The disease is believed to be caused by abnormal metabolism of fats and, although it is often associated with obesity and insulin resistance, it also occurs in lean individuals. NASH is associated with fibrosis (scarring) in the liver that may lead to cirrhosis, liver cancer and death, and the disease also carries an additional risk of death due to heart disease. NASH is now the most common liver disease in the developed world, affecting at least 3 percent of the U.S. population, and there is no approved treatment for the disease.

Mark Pruzanski, MD, founder, President and CEO of Intercept, commented, "We are excited to collaborate with the NIDDK and CRN to test our drug in such a robust NASH study.  Last year we presented data showing that obeticholic acid improved insulin sensitivity, lowered liver enzymes and induced weight loss in type 2 diabetic patients with NAFLD. These results and the novel mechanism of action of our drug are a promising basis for pursuing NASH."  

Pat Robuck, PhD, MPH, the senior advisor for clinical trials in digestive and liver diseases, in the NIDDK's Division of Digestive Diseases and Nutrition, stated, "There is a huge unmet medical need in this patient population. The NIDDK, working together with our NASH CRN investigators, is committed to discovering effective and safe treatments for this serious disease.  The preclinical and clinical data obtained so far with obeticholic acid suggest that it has beneficial effects on glucose metabolism and the liver, and the NASH CRN steering committee thinks it warrants rigorous clinical evaluation in NASH."

About Obeticholic Acid (INT-747)

Obeticholic acid is a potent, first-in-class farnesoid X receptor (FXR) agonist derived from the primary human bile acid chenodeoxycholic acid, the natural endogenous FXR agonist.  Previously known as INT-747, the drug was recently given the generic name of obeticholic acid.  In 2009, the company announced two sets of positive Phase II results from studies in type 2 diabetics with NAFLD and in patients with refractory primary biliary cirrhosis (PBC). These data support obeticholic acid's potential as a novel, hepatoprotective agent in a broad range of chronic liver diseases. Intercept currently plans to advance obeticholic acid into Phase III for PBC, while pursuing additional studies in other indications such as NASH and portal hypertension.  

About Intercept Pharmaceuticals

Intercept is a biopharmaceutical company focused on discovering and developing small molecule drugs for the treatment of chronic fibrotic and metabolic diseases.  The company's most advanced programs are focused on the development of modified bile acids that are selective for FXR, a nuclear receptor, and TGR5, a G protein-coupled receptor. Bile acid signaling through these receptors regulates key aspects of lipid, glucose and overall energy metabolism, while also serving to maintain the functional integrity of the liver, intestine and kidneys, organs that are exposed to bile acid flux.

For more information about Intercept, please go to www.interceptpharma.com.


'/>"/>
SOURCE Intercept Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Intercept Pharmaceuticals Raises $25 Million Series B Financing
2. Intercept Pharmaceuticals Announces Positive Phase II Results for INT-747 as a Treatment for Primary Biliary Cirrhosis
3. Intercept Pharmaceuticals FXR Agonist INT-747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease
4. HemaQuest Pharmaceuticals Raises Additional $4M to Bring Total to $16M in Series B Financing
5. Amylin Pharmaceuticals to Present at the Wedbush Life Sciences Conference 2010
6. Foundation Venture Capital Group Sells Interest in Longevica Pharmaceuticals
7. Onyx Pharmaceuticals Announces Positive Top-Line Carfilzomib Data From Phase 2b Study
8. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide a Clinical Update on Carfilzomib
9. Alexza Pharmaceuticals Appoints Joseph L. Turner to Its Board of Directors
10. Poniard Pharmaceuticals Receives NASDAQ Deficiency Notice Related to Minimum Bid Price
11. Bayer HealthCare Pharmaceuticals Supports New Jersey Governors School in the Sciences at Drew University
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... Cirujanos holandeses han puesto en ... médicos a compartir sus mejores prácticas por el mundo ... médicos de Europa, África, Asia ... aplicación, que combina la transmisión en vivo con mensajería ... Educación   "Imagine un médico de Medicines ...
(Date:5/24/2016)... -- Diana Russell suffers from a form of rheumatoid arthritis ... This disease has put her in a wheelchair, and ... to leave her home.  Because of the size and ... wheelchair.  So if there is a family function, the ... to wait for the bus. Photo - ...
(Date:5/24/2016)... Celsion Corporation (NASDAQ: CLSN ... an update on its ongoing OVATION study, a ... the Company,s DNA-based immunotherapy, with the standard of ... advanced ovarian cancer who will undergo neoadjuvant chemotherapy ... IL-12 DNA plasmid vector formulated as a nanoparticle ...
Breaking Medicine Technology:
(Date:5/28/2016)... ... May 28, 2016 , ... "Color Grading media can be time consuming but ... their media," said Christina Austin - CEO of Pixel Film Studios. , With ... add stylish color grades to their footage. A LUT is a Lookup Table that ...
(Date:5/27/2016)... ... May 27, 2016 , ... Southland Log Homes , designer and manufacturer ... barn kits, which can be found on its website at SouthlandLogHomes.com. , The designs ... and they highlight the craftsmanship of timber post and beam construction. The result ...
(Date:5/27/2016)... ... May 27, 2016 , ... This campaign aims to provide a path ... a society can control and change. , As nearly 795,000 Americans suffering from a ... the United States. Plus, with an estimated 129,000 of these people dying from stroke, ...
(Date:5/27/2016)... NY (PRWEB) , ... May 27, 2016 , ... Aimed ... inspiring human interest stories, which come courtesy of leaders in the nursing and health ... industry, from leading advocates and associations—namely Abilene Christian University. , As the nursing ...
(Date:5/26/2016)... ... May 26, 2016 , ... W.S. Badger Co. ... been honored with a 2016 When Work Works Award for its use of effective ... the national When Work Works project administered by the Families and Work Institute (FWI) ...
Breaking Medicine News(10 mins):